Background Hereditary transthyretin amyloidosis is caused by pathogenic single-nucleotide
variants in the gene encoding transthyretin (TTR) that induce transthyretin misfolding and …

Genome editing has potential for the targeted correction of germline mutations. Here we
describe the correction of the heterozygous MYBPC3 mutation in human preimplantation …

Background Patients with nonobstructive hypertrophic cardiomyopathy (nHCM) often experience
a high burden of symptoms; however, there are no proven pharmacological therapies. …

Background: Mavacamten, an orally administered, small-molecule modulator of cardiac
myosin, targets underlying biomechanical abnormalities in obstructive hypertrophic …

… Judge and Heitner contributed equally to this paper as co-… Judge and Heitner contributed
equally to this paper as co-first … Heitner has received research grants from Pfizer, Eidos, and …

Background Left ventricular outflow tract (LVOT) obstruction is a major determinant of heart
failure symptoms in obstructive hypertrophic cardiomyopathy (oHCM). Aficamten, a next-in-…

Importance Heart failure with reduced ejection fraction is a progressive clinical syndrome,
and many patients’ condition worsen over time despite treatment. Patients with more severe …

Hypertrophic cardiomyopathy (HCM) is a heterogeneous genetic disorder most often caused
by sarcomeric mutations resulting in left ventricular hypertrophy, fibrosis, hypercontractility, …

Background In GALACTIC-HF (Global Approach to Lowering Adverse Cardiac outcomes
Through Improving Contractility in Heart Failure) (n = 8,256), the cardiac myosin activator, …

Importance Exercise limitation is a cardinal manifestation of heart failure with reduced
ejection fraction (HFrEF) but is not consistently improved by any of the current guideline-directed …